MX2009004701A - Analogos selectivos del peptido 2 similar al glucagon. - Google Patents
Analogos selectivos del peptido 2 similar al glucagon.Info
- Publication number
- MX2009004701A MX2009004701A MX2009004701A MX2009004701A MX2009004701A MX 2009004701 A MX2009004701 A MX 2009004701A MX 2009004701 A MX2009004701 A MX 2009004701A MX 2009004701 A MX2009004701 A MX 2009004701A MX 2009004701 A MX2009004701 A MX 2009004701A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- analogues
- substitutions
- peptide
- stomach
- Prior art date
Links
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 title abstract 3
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 210000001072 colon Anatomy 0.000 abstract 2
- 210000002784 stomach Anatomy 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Otolaryngology (AREA)
- Plant Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
Abstract
Se dan a conocer análogos de GLP-2 los cuales comprenden una o más sustituciones en comparación con h[Gly2]GLP-2 y los cuales pueden tener la propiedad de una selectividad incrementada hacia el intestino delgado/colon y estómago/colon. Más particularmente, los análogos preferidos de GLP-2 dados a conocer en este documento comprenden sustituciones en una o más de las posiciones (11, 16, 20, 24) y/o (28) de la secuencia de GLP-2 de tipo silvestre, opcionalmente en combinación con sustituciones adicionales en la posición (2) y una o más de la posiciones (3, 5, 7) y (10) y/o una supresión de uno o más aminoácidos (31) a (33) y/o la adición de una secuencia de péptido estabilizador N-terminal o C-terminal. Los análogos son particularmente útiles para la profilaxis o el tratamiento de trastornos relacionados con el estómago y los intestinos y para mejorar los efectos secundarios de la quimioterapia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200601456 | 2006-11-08 | ||
| US85931306P | 2006-11-15 | 2006-11-15 | |
| PCT/GB2007/004273 WO2008056155A1 (en) | 2006-11-08 | 2007-11-08 | Selective glucagon-like-peptide-2 (glp-2) analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004701A true MX2009004701A (es) | 2009-05-21 |
Family
ID=41232246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004701A MX2009004701A (es) | 2006-11-08 | 2007-11-08 | Analogos selectivos del peptido 2 similar al glucagon. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8642727B2 (es) |
| EP (1) | EP2051995B1 (es) |
| JP (1) | JP5819586B2 (es) |
| KR (1) | KR101527233B1 (es) |
| CN (1) | CN101573376B (es) |
| AU (1) | AU2007319066B2 (es) |
| BR (1) | BRPI0718566A2 (es) |
| CA (1) | CA2669806C (es) |
| EA (1) | EA023886B1 (es) |
| IL (1) | IL198127A (es) |
| MX (1) | MX2009004701A (es) |
| NZ (2) | NZ597554A (es) |
| UA (1) | UA102506C2 (es) |
| WO (1) | WO2008056155A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1877435E (pt) * | 2005-05-04 | 2011-05-24 | Zealand Pharma As | An?logos de p?ptido-2 semelhante a glucagon |
| EP2051995B1 (en) | 2006-11-08 | 2017-02-08 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (glp-2) analogues |
| CN102942626B (zh) * | 2009-03-05 | 2015-11-04 | 江苏豪森医药集团有限公司 | 胰高血糖素样肽-2类似物及其制备方法和用途 |
| EP2311486A1 (en) * | 2009-10-07 | 2011-04-20 | Nestec S.A. | GLP-2 for use in intestine and muscle recovery |
| EP2314616A1 (en) * | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
| CN103003300B (zh) | 2010-04-27 | 2017-06-09 | 西兰制药公司 | Glp‑1受体激动剂和胃泌素的肽缀合物及其用途 |
| WO2012028602A1 (en) | 2010-08-30 | 2012-03-08 | Nycomed Gmbh | Solid phase synthesis of h(gly2)glp-2 |
| BR112014010780A2 (pt) | 2011-11-03 | 2017-04-25 | Zealand Pharma As | conjugados do peptídeo agonista do receptor glp-1-gastrina |
| EP2844670B1 (en) | 2012-05-03 | 2017-12-06 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
| CA2878991C (en) | 2012-07-23 | 2021-12-07 | Zealand Pharma A/S | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| PT3057984T (pt) | 2013-10-17 | 2018-10-24 | Boehringer Ingelheim Int | Análogos de glucagon acilados |
| JP2017503474A (ja) | 2013-11-06 | 2017-02-02 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物 |
| MX2016005556A (es) | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| US10253078B2 (en) | 2014-10-29 | 2019-04-09 | Zealand Pharma A/S | GIP agonist compounds and methods |
| DK3283507T3 (da) | 2015-04-16 | 2020-01-02 | Zealand Pharma As | Acyleret glucagonanalog |
| EA034367B1 (ru) | 2015-10-29 | 2020-01-31 | СиЭлЭс ТЕРАПЬЮТИКС ЛИМИТЕД | Способ повышения безопасности и эффективности противораковой терапии |
| GB2566228A (en) | 2016-06-09 | 2019-03-06 | AmideBio LLC | Glucagon analogs and methods of use thereof |
| EP4424320A3 (en) | 2016-12-09 | 2025-06-11 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| WO2018229252A1 (en) * | 2017-06-16 | 2018-12-20 | Zealand Pharma A/S | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
| WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
| EP3628683A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| WO2020165900A1 (en) | 2019-02-11 | 2020-08-20 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
| CN114945560B (zh) | 2019-10-07 | 2024-08-13 | 卡尔优普公司 | Gpr119激动剂 |
| CN115667277A (zh) | 2020-02-28 | 2023-01-31 | 卡尔优普公司 | Gpr40激动剂 |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| WO2025162422A1 (zh) * | 2024-01-31 | 2025-08-07 | 杭州先为达生物科技股份有限公司 | 胰高血糖素样肽2衍生物及其应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2961045B2 (ja) | 1993-02-24 | 1999-10-12 | 日清製粉株式会社 | 腸管粘膜増強促進剤 |
| US6184208B1 (en) | 1994-06-29 | 2001-02-06 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
| US5789379A (en) * | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| HU229234B1 (en) | 1996-03-01 | 2013-09-30 | Novo Nordisk As | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| DK1231219T3 (da) | 1996-04-12 | 2010-12-20 | Ontario Inc 1149336 | GLucagon-lignende peptid-2 analoger |
| SE9601438D0 (sv) * | 1996-04-16 | 1996-04-16 | Tetra Laval Holdings & Finance | Plattvärmeväxlare |
| US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
| US20020025933A1 (en) | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| US5952301A (en) | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| AU746633B2 (en) | 1997-05-16 | 2002-05-02 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
| US6051557A (en) | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
| CA2819705C (en) | 1998-02-02 | 2014-07-08 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| NZ506839A (en) | 1998-03-09 | 2003-05-30 | Zealand Pharma As | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| AU7421598A (en) | 1998-05-11 | 1999-11-29 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| AU2020501A (en) | 1999-12-08 | 2001-06-18 | 1149336 Ontario Inc. | Chemotherapy treatment |
| JP5161412B2 (ja) | 2000-09-18 | 2013-03-13 | サノス・バイオサイエンス・アクティーゼルスカブ | Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法 |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| WO2002066062A2 (en) | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
| DE60226702D1 (de) | 2001-02-16 | 2008-07-03 | Conjuchem Biotechnologies Inc | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen |
| EP1542712A2 (en) | 2001-06-01 | 2005-06-22 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| PL376223A1 (en) * | 2002-10-14 | 2005-12-27 | Novo Nordisk As | Glucagon - like peptide - 2 variants |
| US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
| EP1608680A2 (en) * | 2003-03-24 | 2005-12-28 | Novo Nordisk A/S | Glp-2 derivatives |
| US20070203058A1 (en) | 2003-09-19 | 2007-08-30 | Novo Nordisk A/S | Novel Glp-1 Derivatives |
| WO2005082404A2 (en) | 2004-02-27 | 2005-09-09 | Novo Nordisk A/S | Glp-2 derivatives modified by lipophilic substituents |
| ES2427150T3 (es) | 2004-11-01 | 2013-10-29 | Nps Pharmaceuticals, Inc. | Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad |
| PT1877435E (pt) | 2005-05-04 | 2011-05-24 | Zealand Pharma As | An?logos de p?ptido-2 semelhante a glucagon |
| EP2051995B1 (en) | 2006-11-08 | 2017-02-08 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (glp-2) analogues |
| US8685919B2 (en) | 2008-12-15 | 2014-04-01 | Zealand Pharma A/S | Glucagon analogues |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| AU2012255119B2 (en) | 2011-05-18 | 2017-04-20 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| EP2844670B1 (en) | 2012-05-03 | 2017-12-06 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
-
2007
- 2007-11-08 EP EP07824505.7A patent/EP2051995B1/en not_active Not-in-force
- 2007-11-08 US US12/514,042 patent/US8642727B2/en not_active Expired - Fee Related
- 2007-11-08 CN CN2007800414908A patent/CN101573376B/zh not_active Expired - Fee Related
- 2007-11-08 CA CA2669806A patent/CA2669806C/en not_active Expired - Fee Related
- 2007-11-08 MX MX2009004701A patent/MX2009004701A/es active IP Right Grant
- 2007-11-08 NZ NZ597554A patent/NZ597554A/en not_active IP Right Cessation
- 2007-11-08 AU AU2007319066A patent/AU2007319066B2/en not_active Ceased
- 2007-11-08 WO PCT/GB2007/004273 patent/WO2008056155A1/en not_active Ceased
- 2007-11-08 KR KR1020097009589A patent/KR101527233B1/ko not_active Expired - Fee Related
- 2007-11-08 JP JP2009535132A patent/JP5819586B2/ja not_active Expired - Fee Related
- 2007-11-08 UA UAA200904559A patent/UA102506C2/ru unknown
- 2007-11-08 BR BRPI0718566-9A patent/BRPI0718566A2/pt not_active Application Discontinuation
- 2007-11-08 EA EA200900667A patent/EA023886B1/ru not_active IP Right Cessation
- 2007-11-08 NZ NZ576260A patent/NZ576260A/en not_active IP Right Cessation
-
2009
- 2009-04-16 IL IL198127A patent/IL198127A/en active IP Right Grant
-
2014
- 2014-02-04 US US14/172,680 patent/US10092648B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR101527233B1 (ko) | 2015-06-08 |
| NZ576260A (en) | 2012-04-27 |
| CN101573376A (zh) | 2009-11-04 |
| CN101573376B (zh) | 2013-11-06 |
| US10092648B2 (en) | 2018-10-09 |
| WO2008056155A1 (en) | 2008-05-15 |
| AU2007319066A1 (en) | 2008-05-15 |
| US20120004392A1 (en) | 2012-01-05 |
| KR20090089308A (ko) | 2009-08-21 |
| IL198127A (en) | 2015-06-30 |
| US8642727B2 (en) | 2014-02-04 |
| EP2051995B1 (en) | 2017-02-08 |
| CA2669806C (en) | 2018-10-02 |
| CA2669806A1 (en) | 2008-05-15 |
| EA200900667A1 (ru) | 2010-06-30 |
| IL198127A0 (en) | 2011-08-01 |
| UA102506C2 (ru) | 2013-07-25 |
| JP5819586B2 (ja) | 2015-11-24 |
| HK1136310A1 (en) | 2010-06-25 |
| EA023886B1 (ru) | 2016-07-29 |
| JP2010509197A (ja) | 2010-03-25 |
| NZ597554A (en) | 2014-04-30 |
| EP2051995A1 (en) | 2009-04-29 |
| US20140154214A1 (en) | 2014-06-05 |
| BRPI0718566A2 (pt) | 2014-03-11 |
| AU2007319066B2 (en) | 2013-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009004701A (es) | Analogos selectivos del peptido 2 similar al glucagon. | |
| UA95235C2 (en) | Glucagon-like-peptide-2 (glp-2) analogues | |
| MX2009006564A (es) | Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico. | |
| WO2009007714A3 (en) | Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour | |
| WO2007056362A3 (en) | Glucagon analogs exhibiting physiological solubility and stability | |
| NZ596037A (en) | Fgf21 mutants and uses thereof | |
| PL1891105T3 (pl) | Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| MX2010012695A (es) | Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico. | |
| IL232501A (en) | Peptide or polypeptide-resistant protein analogs and their uses | |
| PE20121393A1 (es) | Analogo peptidico de oxintomodulina | |
| PT1991680E (pt) | Sistema para a expressão de componentes ortogonais de tradução em células hospedeiras eubacterianas | |
| MX2010002001A (es) | Peptido cdca1 y agente farmaceutico que comprende elmismo. | |
| MX2009012675A (es) | Tensioactivos reconstituidos que tienen propiedades mejoradas. | |
| WO2009032749A3 (en) | Salicylanilide modified peptides for use as oral therapeutics | |
| WO2009030498A3 (en) | Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission | |
| WO2008152140A3 (en) | Recombinant transferrin mutants | |
| WO2010126156A3 (en) | Alkaline protease variants | |
| TW200726842A (en) | Mutant glucose dehydrogenase | |
| MY209410A (en) | Recombinant protein variants | |
| PT1988914E (pt) | Combinação de análogos de somatostatina com diferente selectividade para subtipos do receptor da somatostatina humana | |
| WO2007030519A3 (en) | Stabilized glp-1 analogs | |
| WO2005074626A3 (en) | Compositions, methods and uses for a novel family of peptides | |
| WO2007005738A3 (en) | Glp-1 pharmaceutical compositions | |
| WO2009118710A3 (en) | Cd4-related polypeptides and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |